Xeris Biopharma Holdings Inc
NASDAQ:XERS
Other Pre-Announcement
Xeris Biopharma Reports First Quarter Financial Results And Upcoming Events
Published: 05/11/2022 11:07 GMT
Xeris Biopharma Holdings Inc (XERS) - Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events.
Q1 Loss per Share $0.25.
Ended Q1 With $132.1m in Cash, Cash Equivalents and Short-term Investments.
Xeris Biopharma - Affirming 2022 Guidance for Combined Net Product Revenues of $105m - $120m.
Sees 2022 Year-end Cash Balance of $90m-$110m, and Cash Flow Breakeven by Year-end 2023.
Q1 Earnings per Share View $-0.25 -- Refinitiv Ibes Data (analyst estimates).
Q1 Loss per Share $0.25.
Ended Q1 With $132.1m in Cash, Cash Equivalents and Short-term Investments.
Xeris Biopharma - Affirming 2022 Guidance for Combined Net Product Revenues of $105m - $120m.
Sees 2022 Year-end Cash Balance of $90m-$110m, and Cash Flow Breakeven by Year-end 2023.
Q1 Earnings per Share View $-0.25 -- Refinitiv Ibes Data (analyst estimates).